Abstract
To solve the problem of tumor multidrug resistance in cancer therapy, a new drug delivery system of genipin-cross-linked iron (III) oxide/polyetherimide nanoparticles was used to load doxorubicin and small interfering RNA for combined cancer therapy. The results showed that the drug loading and encapsulation efficiency of doxorubicin could reach 45.39% and 52.18%, respectively. Doxorubicin released from iron (III) oxide-polyetherimide-doxorubicin is about 40% in the first day and 95% in 14 days. When loading doxorubicin and small interfering RNA, small interfering RNA could be absorbed completely. Besides, small interfering RNA could strengthen the anticancer effect when iron (III) oxide-polyetherimide-doxorubicin/small interfering RNA was used for in vitro HeLa cell combined treatment, and the effect of combination group was better than that of the group with doxorubicin alone. In addition, the toxicity of iron (III) oxide-polyetherimide was low when examined by the Alamar Blue assay. Therefore, our results reveal that this new system has potential applications in the future drug combination therapy, especially in the combined targeting drug delivery field.
Highlights
More and more attentions have been paid to the gene and chemotherapy drug combination therapy system.[3]
HeLa cells in the logarithmic phrase were digested with trypsin to obtain single cell suspension and the required cell concentration was adjusted to 2 Â 104 mLÀ1 with RPMI1640 medium containing 10% fetal bovine serum (FBS) and seeded in each well of 96well plates
The anticancer performance of Fe3O4-PEI-DOX/ Small interfering RNA (siRNA) was better than that of Fe3O4-PEI-DOX, which indicated that the combination of drug and siRNA had a better effect than the drug alone when cross-linked in the drug carrier
Summary
Tumor multidrug resistance has been a serious problem in the tumor treatment.[1,2] In recent years, more and more attentions have been paid to the gene and chemotherapy drug combination therapy system.[3] This system has good synergy effect, because exogenous gene can inhibit the expression of the target gene, reduces multidrug resistance, and accelerates cell death. It can reduce the drug dosage, thereby reducing the side effects.[4,5] the combined system is expected to become an effective method of tumor treatment in the future for a better curative effect. It can degrade its complementary pairing mRNA sequence and the complementarity effect can silence the expression of target genes, which is a kind of typical negative regulatory mechanism.[6,7] drug
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
